Roche's ($RHHBY) Genentech unit launched a new late-stage trial testing a two-drug combo in melanoma patients, throwing its hat in the ring with GlaxoSmithKline ($GSK), which is testing a rival combo therapy. Report
| Tuesday, November 3rd | 12pm ET / 9am PT | Presented by: Reed Tech
The FDA's Unique Device Identification (UDI) compliance date of September 24, 2016 for Class II device labelers is now less than one year away. Register today to learn why Class II UDI compliance is the biggest challenge yet, 5 steps to a timely submission, and more.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!